CPRX (Catalyst Pharmaceuticals) YoY EBITDA Growth: 13.94% (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

CPRX Catalyst Pharmaceuticals Inc CPRX
70 GF Score
Price $31.49
GF Value $25.01
Valuation Modestly Overvalued
! 6 Warning Signs
View Full Analysis

What is Catalyst Pharmaceuticals YoY EBITDA Growth?

Catalyst Pharmaceuticals CPRX +0.02% 70 YoY EBITDA Growth is 13.94% as of Mar. 2026. GuruFocus rates CPRX with a GF Score™ of 70/100 and a GF Value™ of $25.01 (Modestly Overvalued). The stock has 6 warning signs investors should review.

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months. Catalyst Pharmaceuticals's YoY EBITDA Growth for the quarter that ended in Mar. 2026 was 13.94%.

Catalyst Pharmaceuticals's EBITDA per Share for the three months ended in Mar. 2026 was $0.65.

Catalyst Pharmaceuticals YoY EBITDA Growth Related Terms

Catalyst Pharmaceuticals YoY EBITDA Growth Historical Data

* Premium members only.

The historical data trend for Catalyst Pharmaceuticals's YoY EBITDA Growth can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Catalyst Pharmaceuticals YoY EBITDA Growth Chart

Catalyst Pharmaceuticals Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
YoY EBITDA Growth
Get a 7-Day Free Trial Premium Member Only Premium Member Only 25.13 89.55 13.73 77.19 24.62

Catalyst Pharmaceuticals Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
YoY EBITDA Growth Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 93.92 16.24 23.91 -2.27 13.94
CPRX
70GF Score
Catalyst Pharmaceuticals Inc CPRX
YoY EBITDA Growth is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Catalyst Pharmaceuticals YoY EBITDA Growth Calculation

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months.

Catalyst Pharmaceuticals's YoY EBITDA Growth for the fiscal year that ended in Dec. 2025 is calculated as:

YoY EBITDA Growth (A: Dec. 2025 )
=(EBITDA per Share (A: Dec. 2025 )-EBITDA per Share (A: Dec. 2024 ))/ | EBITDA per Share (A: Dec. 2024 ) |
=(2.323-1.864)/ | 1.864 |
=24.62 %

Catalyst Pharmaceuticals's YoY EBITDA Growth for the quarter that ended in Mar. 2026 is calculated as:

YoY EBITDA Growth (Q: Mar. 2026 )
=(EBITDA per Share (Q: Mar. 2026 )-EBITDA per Share (Q: Mar. 2025 )) / | EBITDA per Share (Q: Mar. 2025 )) |
=(0.654-0.574)/ | 0.574 |
=13.94 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about YoY EBITDA Growth →
What does a YoY EBITDA Growth of 13.94% mean?
Catalyst Pharmaceuticals (CPRX) has a YoY EBITDA Growth of 13.94% as of Mar. 2026. YoY EBITDA Growth is the percentage change of EBITDA per share over the past 12-month. View historical data for Catalyst Pharmaceuticals and its competitors.
Is Catalyst Pharmaceuticals' YoY EBITDA Growth too high?
Catalyst Pharmaceuticals' current YoY EBITDA Growth is 13.94%. Overall, Catalyst Pharmaceuticals has a GF Score™ of 70/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Catalyst Pharmaceuticals' YoY EBITDA Growth compare to PBLS and ELVN?
Catalyst Pharmaceuticals' YoY EBITDA Growth of 13.94% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good YoY EBITDA Growth for a Biotechnology company?
A good YoY EBITDA Growth depends on the Biotechnology industry context. However, YoY EBITDA Growth should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high YoY EBITDA Growth mean?
A high YoY EBITDA Growth can signal that a stock is expensive relative to its fundamentals. YoY EBITDA Growth is the percentage change of EBITDA per share over the past 12-month. View historical data for Catalyst Pharmaceuticals and its competitors. Catalyst Pharmaceuticals's current YoY EBITDA Growth is 13.94%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Catalyst Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Catalyst Pharmaceuticals (CPRX) is currently considered Modestly Overvalued. The stock's GF Value™ is $25.01, compared to a current price of $31.49 — trading 25.9% above its estimated fair value. The current YoY EBITDA Growth is 13.94%. Catalyst Pharmaceuticals' overall GF Score™ is 70/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is YoY EBITDA Growth calculated?
YoY EBITDA Growth is calculated from a company's financial statements. For Catalyst Pharmaceuticals (CPRX), the current YoY EBITDA Growth is 13.94% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Catalyst Pharmaceuticals (CPRX) Overvalued in 2026?

Based on GuruFocus' analysis, Catalyst Pharmaceuticals stock appears to be overvalued. The current stock price of $31.49 is trading 25.9% above its estimated GF Value™ of $25.01. GuruFocus considers Catalyst Pharmaceuticals to be Modestly Overvalued.

Key valuation signals for CPRX:

  • YoY EBITDA Growth: 13.94%
  • GF Value™: $25.01 vs. price of $31.49 (25.9% above fair value)
  • GF Score™: 70/100 with 6 warning signs

No single metric tells the full story. See the CPRX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Catalyst Pharmaceuticals Business Description

Other Exchanges CN2:Germany
Address 355 Alhambra Circle, Suite 801, Coral Gables, FL, USA, 33134
Catalyst Pharmaceuticals Inc is a commercial-stage, patient-centric biopharmaceutical company focused on in-licensing, developing, and commercializing novel high-quality medicines for patients living with rare and difficult to treat diseases. The Company sells three commercial stage drug products, FIRDAPSE (amifampridine), AGAMREE (vamorolone), and FYCOMPA (perampanel). The Company is currently seeking to further expand its product portfolio, with a focus on acquiring the rights to immediately and near-term accretive assets to treat rare (orphan) diseases across therapeutic areas, including clinical-stage opportunities with established proof of concept.
70GF Score

Get the complete analysis for CPRX

YoY EBITDA Growth is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$31.49
Price
$25.01
GF Value